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ABSTRACT
Adoptive T cell therapy has emerged as a powerful strategy to treat human cancers especially
haematological malignancies. Extension of these therapies to solid cancers remains a signiﬁcant challenge
especially in the context of deﬁning immunological correlates of clinical responses. Here we describe
results from a clinical study investigating autologous Epstein-Barr virus (EBV)-speciﬁc T cells generated
using a novel AdE1-LMPpoly vector to treat patients with nasopharyngeal carcinoma (NPC) either pre-
emptively in at-risk patients with no or minimal residual disease (N/MRD) or therapeutically in patients
with active recurrent/metastatic disease (ARMD). Tolerability, safety and efﬁcacy, including progression-
free survival (PFS) and overall survival (OS), were evaluated following adoptive T-cell immunotherapy.
Twenty-nine patients, including 20 with ARMD and nine with N/MRD, successfully completed T-cell
therapy. After a median follow-up of 18.5 months, the median PFS was 5.5 months (95% CI 2.1 to
9.0 months) and the median OS was 38.1 months (95% CI 17.2 months to not reached). Post-
immunotherapy analyses revealed that disease stabilization in ARMD patients was signiﬁcantly associated
with the functional and phenotypic composition of in vitro-expanded T cell immunotherapy. These
included a higher proportion of effector CD8C T-cells and an increased number of EBV-speciﬁc T-cells with
broader antigen speciﬁcity. These observations indicate that adoptive immunotherapy with AdE1-
LMPpoly-expanded T cells stabilizes relapsed, refractory NPC without signiﬁcant toxicity. Promising clinical
outcomes in N/MRD patients further suggest a potential role for this approach as a consolidation
treatment following ﬁrst-line chemotherapy.
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Introduction
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma
(NPC) is endemic in South-East Asia1. Current estimates indi-
cate that 80,000 new cases of EBV-associated NPC are diagnosed
annually, with the highest incidence occurring in Southern
China2,3. Precision radiotherapy is recommended for early-stage
NPC while concurrent chemoradiotherapy with or without
adjunct chemotherapy is the mainstay of treatment for locore-
gionally advanced disease4-6. In addition, plasma EBV DNA is
considered the most accurate predictive and prognostic bio-
marker of disease diagnosis, treatment response and prognostica-
tion7-11. Despite intensive treatment, 30–40% of patients still
develop locoregional relapse or distant failure. Local salvage
operation with or without post-operative radio/chemotherapy or
a second-course of radiotherapy with or without chemotherapy
can attain a locoregional control rate between 20 and 100%12.
However, salvage treatment is associated with signiﬁcant long-
term treatment-related toxicities including brain necrosis, naso-
pharyngeal mucosal necrosis, palatal ﬁstula and massive bleeding.
Although palliative chemotherapy can offer median progression-
free survival (PFS) between 3 and 9 months for patients with
recurrent or metastatic disease, the overall survival (OS) remains
disappointing13. Novel therapeutic approaches are therefore
required to reduce disease burden in these patients and ideally to
pre-empt relapse in high-risk patients with no radiologically
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demonstrable disease, including those with substantial baseline
and post-treatment levels of plasma EBV DNA7-9,14.
Although latent EBV infection is usually under the strict
control of CD8C cytotoxic T-lymphocytes in immunocompe-
tent individuals, EBV-infected NPC cells are characterized by a
restricted gene expression pattern, typically limited to EBV
nuclear antigen (EBNA) 1, latent membrane protein (LMP) 1
and LMP215. EBNA1 and LMP1&2 are subdominant antigens
that induce low numbers of functionally constrained memory
T-cells which may be readily more susceptible to tumor-medi-
ated immune suppression16, 17. Immunotherapeutic approaches
to improve the frequency and function of LMP/EBNA1-speciﬁc
T-cells may therefore augment current treatment options for
NPC16-18.
We previously reported the preliminary outcome of a phase
I study investigating the use of LMP1&2 and EBNA1-speciﬁc
CTL immunotherapy generated using a novel adenoviral vec-
tor, AdE1-LMPpoly, in a cohort of palliative NPC patients with
active refractory disease19. In the current study, we provide an
extended analysis of a large cohort of NPC patients, including
pre-emptive and therapeutic treatment of patients with no or
minimal residual disease (N/MRD) and with active recurrent/
metastatic disease (ARMD) respectively. We demonstrate that
AdE1-LMPpoly-based T-cell therapy was well tolerated in the
majority of NPC patients with highly encouraging clinical
responses in both pre-emptive and therapeutic settings. We
further show how the phenotypic composition and antigen
speciﬁcity of adoptively transferred T cells is associated with
disease stabilization in ARMD patients.
Results
Patient characteristics
Fifty-two patients were enrolled in this study as shown in the
CONSORT diagram (Fig 1). Six patients were withdrawn prior
to T-cell generation because of further PD after chemotherapy
or secondary active infections. T-cell expansion was unsuccess-
ful from 11 patients, due to either low speciﬁcity or poor yield.
Another 5 patients were excluded from T-cell infusion because
of persistent pneumonia (n D 3) or deteriorating ECOG perfor-
mance status (2 or 3, n D 2). In total, 20 patients with ARMD
and 9 patients with N/MRD received at least two doses of
immunotherapy (range 2 to 6, median 4). The clinical
Figure 1. CONSORT diagram showing NPC patients recruitment, adoptive immunotherapy and clinical follow up.
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characteristics of all patients who received adoptive T-cell ther-
apy are shown in Table 1 and Data Supplement Table S1.
Patient 33 died after the administration of a single dose because
of a lung abscess complicating aspiration pneumonia.
Functional and phenotypic properties of AdE1-LMPpoly
expanded T-cells
AdE1-LMPpoly-expanded products comprised a median of
83.80% CD3C T-cells (Fig 2A). Of all mononuclear cells,
32.20% (median) were CD8C T-cells and 27.70% (median)
were CD4C T-cells. NK cells comprised the majority of the
remaining cells in the therapy. While the majority of patients
had undetectable LMP1/2 and EBNA1-speciﬁc T cell ex vivo,
twenty-three patients generated both LMP1/2-speciﬁc and
EBNA1-speciﬁc T-cells post-expansion, 13 generated only
LMP1/2-speciﬁc T-cells, 1 generated only EBNA1-speciﬁc T-
cells, 6 failed to generate either LMP1/2-speciﬁc or EBNA1-
speciﬁc T-cells, and 3 were not tested due to low cell numbers
(Fig 2B & C). Two patients failed to generate enough T cells for
infusion despite the presence of antigen-speciﬁc T cells. The
majority of LMP/EBNA1 MHC-multimerC CD8C T-cells dis-
played either a central memory (TCM) or an effector memory
(TEM) phenotype (Fig 2D). Most of these cells mobilized
CD107a and expressed interferon (IFN)-g and tumor necrosis
factor (TNF) in response to antigen; a large proportion also co-
expressed interleukin (IL)-2 (Fig. 3A). This polyfunctional pro-
ﬁle was associated with high expression levels of the cytolytic
enzymes granzyme B, granzyme K and perforin in LMP/
EBNA1 MHC-multimerC CD8C T-cells (Fig. 3B). The check-
point molecules PD-1, CTLA-4, LAG-3 and TIM-3 were also
expressed on AdE1-LMPpoly-expanded LMP/EBNA1 MHC-
multimerC CD8C T-cells (Fig. 3C). Univariable and multivari-
able analyses revealed that successful T-cell expansion was sig-
niﬁcantly correlated with age <55 years (P D .035), baseline
white cell count before T-cell harvest (P D .015) and patients
with N/MRD (P D .020) (Data Supplement Table S2).
Safety evaluation
A total of 30 patients had at least 1 T-cell infusion and were
included in the safety evaluation. None of these patients
showed treatment-related grade 4 or grade 5 adverse events
(Table 2). The majority of adverse events that could feasibly be
attributed to T-cell infusion were classiﬁed as grade 1 or grade
2. These events were self-limiting and subsided spontaneously
on the day after T-cell infusion without additional intervention.
Two serious adverse events were recorded, possibly but not
directly related to T-cell therapy. Independent review of the
radiological, pathological and microbiological features associ-
ated with these cases showed that both patients had progressive
tumor necrosis. This was potentially due to T-cell-induced
inﬂammation and cytotoxicity but was more likely associated
with complications of prior treatment for locally recurrent
NPC. There was no evidence of microbial contamination in the
AdE1-LMPpoly-expanded products.
Clinical outcome of T-cell therapy in ARMD and N/MRD
patients
The median overall PFS of NPC patients who completed T-cell
therapy was 5.5 months (95% CI 2.1 to 9.0 months), and the
corresponding 1-year and 2-year PFS rates were 29.4% and
21.5%, respectively (Fig 4A). The median overall survival (OS)
of NPC patients who completed T-cell therapy was 38.1 months
(95% CI 17.2 months to not reached), and the corresponding
1-year and 2-year OS rates were 72.4% and 41.3%, respectively.
The disease control rate in the ARMD group was 60% (12 of 20
patients had stable disease following adoptive therapy). None
of the ARMD patients developed a radiologically conﬁrmed
complete or partial response. Six N/MRD patients maintained
a continuous molecular and radiographic complete response
and were censored for progression analysis. One N/MRD
patient developed PD, and another 2 N/MRD patients were ini-
tially stable and then progressed. The median PFS was signiﬁ-
cantly longer for N/MRD patients (not reached) compared
with ARMD patients (3.2 months, 95% CI 0.4 to 3.7 months,
P < .001) (Fig 4B). Univariable and multivariable analyses
revealed that N/MRD status (hazard ratio, 95% CI 0.03 to 0.42,
P D .002, Table S3) was an independent prognostic factor for
PFS. Furthermore, the median OS was signiﬁcantly longer for
N/MRD patients (not reached, range 21 to 76.5 months)
compared with ARMD patients (15.7 months, range 4.1 to
57.8 months, P < .001) (Fig. 4C). Eight N/MRD patients
(88.9%) were alive at the conclusion of the study. Ten patients
in the ARMD group and 3 patients in the N/MRD group
received post-T-cell infusion chemotherapy. As reported previ-
ously, patient 11 developed signiﬁcant tumor shrinkage and an
excellent partial response to paclitaxel salvage chemotherapy
following the administration of AdE1-LMPpoly-expanded
T-cells.19
Table 1. Clinical characteristics of NPC patients treated with AdE1-LMPpoly T-cells.
ARMD N/MRD
(n D 21) (n D 9)
Median age in years (range) 46 (34–68) 49 (22–66)
Sex
Male 18 8
Female 2 1
Stage on diagnosis
I 2 2
II 2 1
III 7 4
IVA 7 1
IVB 1 1
IVC 2 0
Median number of lines of chemotherapy
before T-cell therapy (range)
3 (1 to 5) 2 (1 to 4)
History of recurrent NPC 21 7
Disease status at ﬁrst T-cell infusion
No radiological disease 0 9
Local recurrence 11 0
Regional nodal recurrence 6 0
Lung metastasis 9 0
Liver metastasis 5 0
Bone metastasis 5 0
Distant nodal metastasis 4 0
Median plasma EBV DNA copies/mL
before T-cell therapy (range)
2.3 £ 103
(0 to 6.3 £ 106)
0 (0)
Abbreviations: ARMD, active recurrent/metastatic disease; EBV DNA, Epstein-Barr
virus deoxyribonucleic acid; N/MRD, no or minimal residual disease; NPC, naso-
pharyngeal carcinoma.
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AdE1-LMPpoly-generated T-cell correlates of clinical
response
The identiﬁcation of immune correlates that predict disease
control remains a signiﬁcant challenge, especially in the ﬁeld of
solid tumors. Quantitative analysis of circulating LMP/EBNA1-
speciﬁc T-cell responses in ARMD patients following adoptive
immunotherapy revealed no signiﬁcant correlations with out-
come (data not shown). To explore other correlates we com-
pared survival, and T cell phenotype and speciﬁcity in ARMD
patients who had SD or PD. ARMD patients with SD had a
median PFS of 5.5 months and OS of 18 months, while ARMD
patients with PD had a median PFS of 1 month and OS of
13.5 months. We noted that the proportion of CD8C T-cells in
the administered AdE1-LMPpoly-expanded product was
signiﬁcantly lower for ARMD patients with PD compared with
ARMD patients with SD (Fig 5A). Interestingly, both ARMD
patients with SD and N/MRD patients showed a comparable
proportion of CD8C T cells. Similarly, we noted that ARMD
patients with SD and N/MRD patients received a signiﬁcantly
higher number of LMP/EBNA1-speciﬁc T-cells compared with
ARMD patients with PD (Fig 5B). The AdE1-LMPpoly-
expanded products from ARMD patients with SD and N/MRD
patients were also more likely to contain T-cells that recognized
both LMP1&2 and EBNA1 compared with those from ARMD
patients with PD (Fig 5C). We also assessed the functional and
phenotypic attributes of the CD8C T-cells administered to
ARMD patients. Although not signiﬁcant, we found that dis-
ease stabilization was associated with a trend towards increased
numbers of effector CD8C T-cells (Fig 5D). A similar trend
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Figure 2. Functional and phenotypic characteristics of AdE1-LMPpoly-expanded T-cells (A) The phenotypic characteristics of AdE1-LMPpoly-stimulated T-cells were
assessed by measuring the surface expression of CD14 (monocytes), CD19 (B cells), CD16 (NK cells), CD3 (T-cells), CD4 (CD4 T-cells) and CD8 (CD8 T cells). (B) AdE1-
LMPpoly-stimulated T-cells were assessed for the intracellular production of IFN-g following recall with pools of CD8C T-cell epitopes derived from LMP1&2 or EBNA1.
The data represent the frequencies of LMP1&2-speciﬁc or EBNA1-speciﬁc IFN-g-producing T-cells in all patients. (C) The data represent the number of patients generating
either LMP1&2-speciﬁc and/or EBNA1-speciﬁc T-cells. (D) The memory characteristics of MHC-multimerC T-cells were determined by measuring the surface expression of
CCR7, CD45RA, CD27, CD28 and CD57. T-cell phenotype was determined as follows: Na€ıve (TN) CD45RA
CCCR7C; Central Memory (TCM) CD45RA¡CD27C/¡CD28CCD57¡;
Effector Memory (TEM) CD45RA
¡CD27¡/CCD28¡CD57C/¡; Effector Memory RA (TEMRA) CD45RACCD27¡/CCD28¡/CCD57C.
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between groups was observed for CD8C T-cells expressing
checkpoint molecules, most notably CTLA-4 (Fig 5E). There
was no correlation between either pre-treatment or post-treat-
ment plasma EBV DNA load and PFS in patients with ARMD
(data not shown). Collectively, these analyses suggest that
qualitative aspects of the T-cell infusate may inﬂuence immu-
notherapeutic outcomes in patients with NPC.
Discussion
NPC remains a signiﬁcant problem in endemic regions of South-
east Asia. However, the deﬁned association with EBV infection
provides a platform to develop virus-speciﬁc therapeutic
approaches20-25. In this study, we explored the use of an adoptive
cellular therapy targeting the LMP1&2 and EBNA1 antigens
expressed in NPC. The AdE1-LMPpoly vector rapidly expanded
T-cells with improved functional and cytolytic potential com-
pared with EBV-speciﬁc T-cells manufactured previously using a
different approach based on stimulation with lymphoblastoid cell
lines (LCLs) stimulation26. These autologous AdE1-LMPpoly-
expanded T cells were associated predominantly with self-limit-
ing grade 1 and grade 2 adverse events in NPC patients. Lung
abscesses were recorded as grade 3 events in 2 of 30 patients,
but most likely represented complications of prior treatment for
locally recurrent NPC. Clinical beneﬁt was also observed after
the adminstration of AdE1-LMPpoly-expanded T-cells, objecti-
ﬁed by disease stabilization in ARMD patients and remarkably
long (not yet deﬁned) PFS and OS in N/MRD patients.
Table 2. Safety proﬁles after T-cell therapy.
Adverse events n D 30 (%)
Grade 1 10 (33.3%)
Fatigue 1 (3.3%)
Dry cough 1 (3.3%)
Fever 3 (10%)
Chills 1 (3.3%)
Chest pain 1 (3.3%)
Sore throat 1 (3.3%)
Hyperbilirubinemia 1 (3.3%)
Altered hearing ability 1 (3.3%)
Grade 2 6 (20%)
Fatigue 2 (6.7%)
Fever 1 (3.3%)
Dyspnea 1 (3.3%)
Headache 1 (3.3%)
Vomiting 1 (3.3%)
Grade 3 2 (6.7%)
Lung abscess 2 (6.7%)
CTLA-4LAG-3TIM-3PD-1
0
50
100
0
50
100
GzmB GzmK prf
Figure 3. Polyfunctional cytokine proﬁle and the expression of effector and co-inhibitory molecules in AdE1-LMPpoly-expanded T-cells. (A) AdE1-LMPpoly-stimulated T-
cells were assessed for intracellular cytokine production (IFN-g , TNF, IL-2) and degranulation (CD107a) following recall with pools of LMP/EBNA1-encoded CD8C T-cell
epitopes. The data represent the proportion of the total antigen-speciﬁc T-cells producing each combination of effector functions. (B, C) MHC-multimerC CD8C T-cells in
the AdE1-LMPpoly T-cell products were assessed for intracellular expression of the cytolytic enzymes granzyme B (GzmB), granzyme K (GzmK) and perforin (Prf), or for sur-
face expression of the co-inhibitory receptors PD-1, TIM-3, LAG-3 and CTLA-4. The data represent the proportion of MHC-multimerC CD8C T-cells expressing (B) effector
molecules or (C) co-inhibitory receptors.
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The AdE1-LMPpoly vector was designed to promote the opti-
mal expansion of LMP/EBNA1-speciﬁc T-cells from low frequency
precursors17,28. Consistent with our previous observations, LMP/
EBNA1-speciﬁc T-cells could be generated from the majority of
NPC patients. This contrasts with the use of EBV-transformed
LCLs, which stimulate detectable LMP-speciﬁc T-cells in only half
of all cellular products21,24,28,. Recent studies using LCL-generated
products have shown the potential beneﬁt of LMP-speciﬁc T-cells
in the treatment of NPC. Objective clinical responses including
both complete and partial responses have been detected in patients
following T cell therapy and the presence of LMP2-speciﬁc T cells
has been associated with improved clinical responses when T cells
were delivered as a consolidative treatment to standard chemother-
apy24,26,28.While differences in patient cohortsmay account for dif-
ferences in responses in the current study and previous studies, the
capacity to optimise LMP/EBNA1-speciﬁc T-cell numbers with
the AdE1-LMPpoly vector should provide a platform to further
improve clinical outcome in NPC patients. In line with this possi-
bility, we found evidence for an association between disease stabili-
zation and the number of LMP/EBNA1-speciﬁc T-cells
administered to ARMD patients. Future optimization of LMP/
EBNA-1-speciﬁc T-cell frequencies, potentially via the use of allo-
geneic “off-the-shelf” products, may further enhance the quality
and efﬁcacy of adoptive T-cell therapies29-31.
One approach that could potentially improve the therapeu-
tic beneﬁt of adoptive immunotherapy in NPC patients is its
application in patients with minimal residual disease who are
at a high risk of relapse. Recent observations have shown that
patients with residual plasma EBV DNA titers after standard
radio/chemotherapy are at much higher risk of relapse32,33. In
the current study, we found that LMP/EBNA1-speciﬁc T-cells
were generated more consistently from N/MRD patients. Early
intervention may therefore promote greater T-cell expansions
compared with identical approaches in highly pre-treated
patients with refractory disease. This notion is supported by
the observation that plasma EBV DNA was undetectable at
baseline in the present cohort of N/MRD patients.
Signiﬁcant functional and phenotypic differences were appar-
ent in the cellular products generated from NPC patients follow-
ing AdE1-LMPpoly-based T-cell stimulation. Furthermore, we
detected associations between disease stabilization and the num-
ber of LMP/EBNA1-speciﬁc T-cells, the proportion of CD8C
T-cells and the expression of effector molecules in the adoptively
transferred infusate. Checkpoint molecules were also upregulated
on the expanded LMP/EBNA1-speciﬁc T-cells. Although the
role of immunoregulatory molecules has not been fully eluci-
dated in this setting, clinical observations suggest that PD-L1 is
expressed on NPC cells and may be associated with poor
Figure 4. Kaplan-Meier curves showing (A) progression-free survival in the whole study population, (B) progression-free survival stratiﬁed by active recurrent/metastatic
disease (ARMD) and no or minimal residual disease (N/MRD), and (C) overall survival from the time of recruitment stratiﬁed by ARMD and N/MRD.
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outcome34. Given the observed expression of PD-1 on the major-
ity of LMP/EBNA1-speciﬁc T-cells, these ﬁndings suggest that
PD-1:PD-L1 blockade could potentiate the efﬁcacy of EBV-spe-
ciﬁc immunotherapy in NPC patients35.
In conclusion, the current study demonstrates that adoptive
immunotherapy with AdE1-LMPpoly-stimulated T-cells is well
tolerated in ARMD and N/MRD patients. Our results have also
paved the way for an ongoing phase I/II study investigating the
safety and efﬁcacy of adoptive T-cell transfer as consolidation
therapy in patients with minimal residual disease following
ﬁrst-line chemotherapy for metastatic NPC (ACTRN126130
00866707).
Materials and methods
Patient recruitment
This prospective study was conducted according to the princi-
ples of the Declaration of Helsinki and approved by the
QIMR Berghofer Medical Research Institute Human Research
Ethics Committee, the Institutional Review Board of The
University of Hong Kong/Hospital Authority Hong Kong
West Cluster and the Metro South Human Research Ethics
Committee before commencement. This study was registered
under the Australia New Zealand Clinical Trial Registry
(ACTRN12609000675224). Two cohorts of NPC patients were
recruited from January 2008 to December 2015. The ﬁrst
cohort included 41 ARMD patients with histologically and/or
radiologically conﬁrmed local, regional or distant relapse of
NPC after primary radical radiotherapy/chemoradiotherapy.
Most of these patients had been treated with at least one line of
palliative chemotherapy and/or surgery. The second cohort of
11 N/MRD patients received adoptive T-cell therapy while in
disease remission after primary treatment or successful salvage
treatment for locoregional recurrence or oligometastasis. Writ-
ten informed consent was obtained in all cases. Baseline staging
investigations included magnetic resonance imaging with T1,
T2 and T1-gadolinum enhanced sequences of the head and
neck or computed tomography (CT) scans with contrast of the
head and neck, chest and abdomen before peripheral blood T-
cell harvest, therapy manufacture, and infusion. Plasma EBV
DNA was also measured at baseline. Disease stage at initial
diagnosis was classiﬁed according to the American Joint Com-
mittee on Cancer staging manual 7th edition.
Manufacture and adoptive transfer of LMP/EBNA1-speciﬁc
T-cells
The clinical grade AdE1-LMPpoly vector used in this study has
been described previously19. The AdE1-LMpoly vector contains
a polyepitope of 16 HLA-restricted LMP1&2 epitopes fused to
a truncated gly/ala deleted EBNA1 gene36. To generate LMP/
EBNA1-speciﬁc T-cells, peripheral blood mononuclear cells
(PBMCs) were ﬁrst harvested from 100–300 mL of venous
blood. The AdE1-LMPpoly vector was then used to infect 30%
of the PBMCs (MOI of 10:1), which were then irradiated and
co-cultured with the remaining PBMCs for two weeks. Cultures
were supplemented with fresh growth medium and 120 IU/mL
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Figure 5. Impact of phenotype and antigen speciﬁcity of administered T-cells on the clinical response to adoptive immunotherapy. (A) The frequency of CD8C T-cells in
the AdE1-LMPpoly-expanded product administered to N/MRD and ARMD (stable disease [SD] vs progressive disease [PD]) patients. (B) The total number of LMP/EBNA1-
speciﬁc T-cells infused into N/MRD and ARMD (SD vs PD) patients. (C) The percentage of N/MRD and ARMD (SD vs PD) patients who received a product containing CD8C
T-cells speciﬁc for either LMP1&2 and EBNA1 or LMP1&2 alone. (D) The percentage of T-cells expressing granzyme B (GzmB), granzyme K (GzmK) or perforin (Prf) in the
total lymphocyte population administered to N/MRD and ARMD (SD vs PD) patients. (E) The percentage of T-cells expressing PD-1, TIM-3, LAG-3 or CTLA-4 in the total
lymphocyte population administered to N/MRD and ARMD (SD vs PD) patients.
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of recombinant IL-2 every 3–4 days (Komtur Pharmaceuticals).
Expanded T-cells were tested for antigen speciﬁcity and micro-
bial contamination prior to release for infusion. A summary of
the number of infusions and the absolute number of transferred
T-cells is shown in Table 1 and Table S1.
Intracellular cytokine assay
For analysis of LMP1&2-speciﬁc and EBNA1-speciﬁc T-cell
frequencies, AdE1-LMPpoly-expanded products were stimu-
lated for 4 hours in the presence of GolgiPlug (BD Biosciences)
with a pool of deﬁned epitopes from LMP1&2 or EBNA1 or
with an overlapping set of peptides encompassing the whole
EBNA1 protein (all from Mimotopes, GenScript or JPT Tech-
nologies), and then assessed for the intracellular production of
IFN-g. For multiparametric analysis, cells were stimulated for
4 hours in the presence of GolgiPlug and GolgiStop (BD Bio-
sciences) with the peptides listed above and anti-CD107a-FITC
(BD Biosciences). Cells were then washed and stained with
anti-CD8-PerCPCy5.5 (eBioscience) and anti-CD4-PECy7 (BD
Biosciences), ﬁxed and permeabilised with Cytoﬁx/Cytoperm
(BD Biosciences), washed again and stained with anti-IFN-
g-AF700, anti-IL-2-PE and anti-TNF-APC (all from BD Bio-
sciences). After a further wash, cells were resuspended in PBS
and acquired using a BD LSR Fortessa with FACSDiva software
(BD Biosciences). Post-acquisition and Boolean analysis was
performed using FlowJo software (TreeStar).
Polychromatic proﬁling of T-cell phenotype
T-cells were incubated for 20 minutes at 4C with APC-
labelled MHC class I multimers speciﬁc for the HLA-A11-
restricted epitope SSCSSCPLSKI (LMP2A), the HLA-A24-
restricted epitope TYGPVFMCL (LMP2A) or the HLA-Cw03-
restricted epitope FVYGGSKTSL (EBNA1). For assessment of
surface phenotype, cells were then incubated for a further
30 minutes at 4C with the following antibody panels: (i) anti-
CD3-AF700, anti-CD4-PECy7 and anti-CD8-V500; (ii)
anti-CD4-AF700, anti-CD8-V500, anti-CD14-eFluor450, anti-
CD19-eFluor450 and anti-CD56-PECy7; (iii) anti-CD4-
PECy7, anti-CD8-V500, anti-CD27-PE, anti-CD28-
PerCPCy5.5, anti-CD45RA-FITC, anti-CCR7-AF700 and
anti-CD57-biotin followed by steptavidin conjugated to Cas-
cade Yellow; or (iv) anti-CD4-PECy7, anti-CD8-V500, anti-
TIM-3-PE, anti-LAG-3-FITC and anti-PD-1-BV786. For
intracellular analysis, cells were treated with TF Fixation/Per-
meabilization buffer (BD Biosciences) and then stained in the
presence Perm/Wash with the following antibodies: (i) anti-
perforin-BV421, anti-granzyme B-AF700 and anti-granzyme
K-FITC; or (ii) anti-CTLA-4-BV421. Cells were acquired
using a BD LSR Fortessa with FACSDiva software (BD Bio-
sciences) and post-acquisition analysis was performed using
FlowJo software (TreeStar).
Clinical response evaluation
Patients with successful T-cell expansion and satisfactory East-
ern Cooperative Oncology Group (ECOG) performance status
(0 or 1) received a minimum of 2 infusions at fortnightly
intervals and a total dose of between 4.9 £ 107 and 2.4 £ 108
AdE1-LMPpoly-expanded T-cells. One patient who received a
single T-cell infusion was included only in the safety analysis.
Patients were monitored fortnightly for tolerability and safety.
MRI with T1, T2 and T1-gadolinum-enhanced sequence or CT
scans with contrast of the head and neck were performed at 1,
2, 3, 4 and 6 months after ﬁrst T-cell infusion and then every
3 months until progressive disease (PD), as we previously
described.19 Surveillance CT scans with contrast of the thorax
and abdomen were also performed every 3 months until PD.
Acute and long-term toxicities were graded according to ver-
sion 3.0 of the Common Terminology Criteria for Adverse
Events (CTCAE).37 Best objective responses were determined
according to version 1.1 of the Response Evaluation Criteria in
Solid Tumors (RECIST).38
Statistical analysis
PFS was calculated from the date of ﬁrst T-cell infusion to the
date of radiologically documented PD or the date of death.
Patients who were alive and without PD were censored at their
last follow-up. Mann-Whitney U tests were used to compare
means between groups when there was evidence of deviation
from normality assumptions. Log-rank tests were employed for
subgroup comparisons of PFS. Binary logistic regressions with
univariable and multivariable analyses were performed for fac-
tors correlated with successful T-cell expansion. Cox propor-
tional hazard models with univariable and multivariable
analyses were performed for prognostic factors of PFS. Data for
plasma EBV DNA titers were log-transformed and analyzed on
the log scale longitudinally. Time-dependent covariate Cox
models were applied when considering the effect of log plasma
EBV DNA titers and fold change in plasma EBV DNA levels
from baseline. Statistical signiﬁcance was deﬁned as P < .05
(two-sided), and adjustment for multiple comparisons among
group means was based on the Sidak method. All statistical
analyses were performed using Prism 6 Software (GraphPad),
Stata 13 (StataCorp LP), and Statistical Package for Social Sci-
ences (SPSS) version 23.
Disclosure of potential conﬂicts of interest
RK holds an international patent on Ad-E1LMPploy immunotherapy.
None of the other authors declare any conﬂict of interest related to the
data presented in this manuscript.
Acknowledgements
We thank the staff at Q-Gen Cell Therapeutics for their support during the
production of T-cell therapies and for extensive microbiological testing.
Funding
This study was supported by funding from the QIMR Berghofer Immuno-
therapy Flagship Program, the Ester Lee and Chew Pik Foundation, the
Croucher Foundation and many other generous donors. DAP is a Well-
come Trust (UK) Senior Investigator. RK is supported by a National
Health and Medical Research Council (Australia) Senior Principal
Research Fellowship.
e1273311-8 C. SMITH ET AL.
References
1. Ho JHC. Nasopharyngeal carcinoma (NPC). Advances in Cancer
Research 1972; 16:57-92; PMID:4333791
2. Zeng Y. Seroepidemiological studies on nasopharyngeal carcinoma in
China. Advances in Cancer Research 1985; 44:121-38; PMID:2994402
3. Senba M, Zhong XY, Senba MI, Itakura H. EBV and nasopharyngeal
carcinoma. Lancet 1994; 343:1104; PMID:7909127
4. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J et al. Chemo-
therapy and radiotherapy in nasopharyngeal carcinoma: an update of
the MAC-NPC meta-analysis. Lancet Oncol 2015; 16:645-55
5. Lee AW, Ma BB, Ng WT, Chan AT. Management of Nasopharyngeal
Carcinoma: Current Practice and Future Perspective. J Clin Oncol
2015; 33:3356-64
6. Sze H, Blanchard P, Ng WT, Pignon JP, Lee AW. Chemotherapy for
Nasopharyngeal Carcinoma - Current Recommendation and Contro-
versies. Hematology/oncology clinics of North America 2015;
29:1107-22
7. Chan AT, Lo YM, Zee B, Chan LY,Ma BB, Leung SF et al. Plasma Epstein-
Barr virusDNAand residual disease after radiotherapy for undifferentiated
nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94:1614-9
8. Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC et al. Plasma
Epstein-Barr viral DNA load at midpoint of radiotherapy course pre-
dicts outcome in advanced-stage nasopharyngeal carcinoma. Ann
Oncol 2014; 25:1204-8
9. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M et al. Plasma Epstein-
Barr viral deoxyribonucleic acid quantitation complements tumor-
node-metastasis staging prognostication in nasopharyngeal carci-
noma. J Clin Oncol 2006; 24:5414-8
10. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS et al. Quan-
tiﬁcation of plasma Epstein-Barr virus DNA in patients with advanced
nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461-70
11. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT et al. Quanti-
tative analysis of cell-free Epstein-Barr virus DNA in plasma of
patients with nasopharyngeal carcinoma. Cancer Res 1999; 59:1188-91
12. Wei WI, Kwong DL. Recurrent nasopharyngeal carcinoma: surgical
salvage vs. additional chemoradiation. Current opinion in otolaryn-
gology & head and neck surgery 2011; 19:82-6; PMID:21412154;
http://dx.doi.org/10.1097/MOO.0b013e328344a599
13. Chan OS, Ngan RK. Individualized treatment in stage IVC nasopha-
ryngeal carcinoma. Oral Oncol 2014; 50:791-7
14. Leonard WJ. The defective gene in X-linked severe combined immu-
nodeﬁciency encodes a shared interleukin receptor subunit: implica-
tions for cytokine pleiotropy and redundancy. Current Opinion in
Immunology 1994; 6:631-5; PMID:7946053
15. Nicholls J, Hahn P, Kremmer E, Fr€ohlich T, Arnold GJ, Sham J et al.
Detection of wild type and deleted latent membrane protein 1 (LMP1)
of Epstein-Barr virus in clinical biopsy material. Journal of virological
methods 2004; 116:79-88
16. Smith C, and Khanna R.. Polyepitope Vaccines for Human Cancers
Hoboken, NJ: John Wiley and Sons, Inc., 2007.
17. Smith C, Cooper L, Burgess M, Rist M, Webb N, Lambley E et al.
Functional reversion of antigen-speciﬁc CD8C T cells from
patients with Hodgkin lymphoma following in vitro stimulation
with recombinant polyepitope. The Journal of Immunology 2006;
177:4897-906
18. Smith C, Khanna R. Generation of cytotoxic T lymphocytes for
immunotherapy of EBV-associated malignancies. Methods in Molecu-
lar Biology (Clifton, NJ) 2010; 651:49-59
19. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V et al. Effective treat-
ment of metastatic forms of Epstein-Barr virus-associated nasopha-
ryngeal carcinoma with a novel adenovirus-based adoptive
immunotherapy. Cancer Res 2012; 72:1116-25
20. Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F et al.
Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-speciﬁc cyto-
toxic T cells with in vitro antitumor activity boosts LMP2-speciﬁc
immune response in a patient with EBV-related nasopharyngeal carci-
noma. Ann Oncol 2004; 15:113-7
21. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for
EBV-associated malignancies. Leuk Lymphoma 2005; 46:1-10
22. Lutzky VP, Corban M, Heslop L, Morrison LE, Crooks P, Hall DF
et al. Novel approach to the formulation of an Epstein-Barr virus anti-
gen-based nasopharyngeal carcinoma vaccine. J Virol 2010; 84:407-17
23. Moss D, Khanna R, Bharadwaj M. Will a vaccine to nasopharyngeal
carcinoma retain orphan status? Developments in biologicals 2002;
110:67; PMID:12477308
24. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC
et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr
virus–speciﬁc T lymphocytes. Blood 2005; 105:1898-904
25. Yufeng D, Guocheng Z, Dongliang X, Rong F, Yuhong C, Ruying L
et al. Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-
cell response against pediatric nasopharyngeal carcinoma in vitro.
Medical oncology 2009; 26:78-85
26. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT
et al. Adoptive transfer of EBV-speciﬁc T cells results in sustained
clinical responses in patients with locoregional nasopharyngeal carci-
noma. J Immunother 2010; 33:983-90
27. Smith C, Beagley L, Khanna R. Acquisition of polyfunctionality by
Epstein-Barr virus-speciﬁc CD8C T cells correlates with increased
resistance to galectin-1-mediated suppression. J Virol 2009; 83:6192-8
28. Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM et al. Adoptive
T-cell transfer and chemotherapy in the ﬁrst-line treatment of meta-
static and/or locally recurrent nasopharyngeal carcinoma. Mol Ther
2014; 22:132-9
29. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubro-
vin M et al. Successful treatment of EBV-associated posttransplanta-
tion lymphoma after cord blood transplantation using third-party
EBV-speciﬁc cytotoxic T lymphocytes. Blood 2010; 116:5045-9
30. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin
JH et al. Multicenter study of banked third-party virus-speciﬁc T cells
to treat severe viral infections after hematopoietic stem cell transplan-
tation. Blood 2013; 121:5113-23
31. Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin
J et al. Graft versus leukemia response without graft-versus-host dis-
ease elicited by adoptively transferred multivirus-speciﬁc T-cells. Mol
Ther 2015; 23:179-83
32. Hsu CL, Chang KP, Lin CY, Chang HK, Wang CH, Lin TL et al.
Plasma Epstein-Barr virus DNA concentration and clearance rate as
novel prognostic factors for metastatic nasopharyngeal carcinoma.
Head Neck 2012; 34:1064-70
33. Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY et al.
Plasma EBV DNA clearance rate as a novel prognostic marker for
metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res
2010; 16:1016-24
34. Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W et al. Co-expres-
sion of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal
carcinoma. Medical oncology 2015; 32:86
35. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T et al. EBV-driven
LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carci-
noma: Implications for oncotargeted therapy. Oncotarget 2014;
5:12189-202
36. Smith C, Cooper L, Burgess M, Rist M, Webb N, Lambley E et al.
Functional reversion of antigen-speciﬁc CD8C T cells from patients
with Hodgkin lymphoma following in vitro stimulation with recombi-
nant polyepitope. J Immunol 2006; 177:4897-906
37. Cancer Therapy Evaluation Program, Common Terminology Criteria
for Adverse Events (CTCAE) v4.0. National Cancer Institute (NIH)
USA, 2016:http://ctep.cancer.gov/protocolDevelopment/electronic_ap
plications/ctc.htm
38. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford
R et al. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47
ONCOIMMUNOLOGY e1273311-9
